Treatment and the treatment process

Leukemia that does not respond to treatment

Sometimes leukemia does not respond to the first treatment as expected. This is called refractory leukemia. This topic explains what it means and what steps are possible.

Last updated: 14 October 2026~2 min read

A dark navy corridor: one closed door, and further along other doors glowing teal and gold. — **Figure 1.**When one treatment does not work, other paths remain.

01Short answer

Refractory (treatment-resistant) leukemia is when remission or the target response is not reached after standard treatment — for example, no remission in AML after one or two induction courses, or CML on a TKI not meeting molecular targets on time. Causes can include ways leukemia cells protect themselves from a drug, new mutations, or the drug not being taken consistently. In such cases, doctors re-test the bone marrow and genetics, then choose treatment with a different mechanism: targeted drugs (based on FLT3, IDH or BCR::ABL1 mutations), immunotherapy (blinatumomab, inotuzumab, CAR-T), salvage chemotherapy, an allogeneic transplant where possible, or a clinical trial. Symptom control and palliative care matter at every stage.

02Simple explanation

What is refractory? The leukemia did not shrink enough after treatment.

Why does it happen? Some cells "learn" to protect themselves from the drug.

Next step. Repeat tests and a different treatment.

Comfort. Easing symptoms is always part of the plan.

03Scientific explanation

Definition: in AML, by ELN criteria, no complete remission after one or two intensive inductions; in ALL, no remission after induction or persistent MRD; in CML, ELN "failure" milestones (for example BCR::ABL1 >1% at 12 months).

Mechanisms: kinase domain mutations (such as T315I), activation of bypass signalling pathways, drug efflux pumps, loss of the target antigen (such as CD19-negative relapse) and clonal evolution.

Approach: a repeat genetic panel, a search for possible targets and reassessment of fitness; once remission is reached, bridging therapy to transplant. The NCI particularly recommends clinical trials for refractory disease.

04What happens in the body?

First step: re-checking

Doctors first check the diagnosis, whether the drug was taken correctly and whether the leukemia has new changes. Sometimes a new mutation opens the way to a new targeted drug.

A leukemia cell shielded faintly against one beam while a key of light approaches from another side. — **Figure 2.**With resistance, a different mechanism is chosen.

Options

Salvage chemotherapy, targeted drugs, immunotherapy and transplant can complement each other. The choice depends on the leukemia type, earlier treatment and general health.

Clinical trials

Trials can give access to new drugs not yet widely used. Taking part is voluntary; discuss the benefits, risks and burden with your doctor.

A calm modern laboratory at night with glowing sample racks and a warm light over a bench. — **Figure 3.**Clinical trials open the way to new treatments.

05The path when there is no response

A simplified outline.

1Re-checkMarrow and genetics.

2CauseMutation, adherence, resistance.

3New planA different mechanism.

4ComfortSymptom control.

OptionsOften available.

TargetBased on a new mutation.

SupportPalliative team.

06Possible options in refractory leukemia

Option	Example	For whom?
Salvage chemotherapy	FLAG-Ida and others	If fit enough
Targeted drug	FLT3, IDH, BCR::ABL1 inhibitors	If a matching mutation is present
Immunotherapy	Blinatumomab, inotuzumab, CAR-T	Mainly B-ALL
Allogeneic transplant	After remission	Suitable donor and health
Clinical trial	New drugs	Those meeting criteria
Palliative care	Pain, breathing, tiredness	At every stage

* Simplified table; you make the choice together with your doctor.

07Key terms

Refractory: Not responding to treatment.
Salvage treatment: Treatment given when the first did not work.
Clonal evolution: New genetic changes arising in the leukemia.
Bridging therapy: Treatment that holds the disease until transplant.
Palliative care: Care that improves symptoms and quality of life.
Antigen loss: A target marker disappearing from the cell.

08Key points

Refractory does not mean options have run out.
Repeat tests matter.
Drugs with another mechanism may help.
Clinical trials are an option.
Palliative care can go alongside treatment.
Ask your questions openly.

09Frequently asked questions

Is this my fault?

No. Resistance is mostly a biological feature of the leukemia.

How can I find a clinical trial?

Ask your doctor; official registries also exist (such as ClinicalTrials.gov).

Can I decline treatment?

Yes, that is your right; symptom care continues in that case too.

How do I tell my family?

A doctor, psychologist or social worker can help with that conversation.

10Questions for your doctor

Take these questions to your appointment. The ones you save are collected on the “My questions” page and stay on this device only.

Is this my fault?
How can I find a clinical trial?
Can I decline treatment?
How do I tell my family?

My questions

12Sources

National Cancer Institute (NCI). Adult Acute Myeloid Leukemia Treatment (PDQ) – Patient Version
National Cancer Institute (NCI). Adult Acute Lymphoblastic Leukemia Treatment (PDQ) – Patient Version
Leukemia & Lymphoma Society. Relapsed and refractory leukemia
National Cancer Institute (NCI). Targeted Therapy to Treat Cancer
National Cancer Institute (NCI). Clinical Trials Information for Patients and Caregivers
World Health Organization. Palliative care
American Cancer Society. Blood Transfusion Side Effects
American Cancer Society. Low Platelet Count (Thrombocytopenia)
American Cancer Society. Managing Anemia When You Have Cancer
JAMA, 2023. Red Blood Cell Transfusion: 2023 AABB International Guidelines

Medical disclaimerThis information is for educational purposes only and does not replace medical advice.

Last updated: 14 October 2026← Back to the list

Open the interactive site →